The aim of this study was to explore the antitumor activity of these shikonin derivatives in murine BCL1 chronic lymphocytic leukemia cells and in human JVM-13 B-cell prolymphocytic leukemia to delineate a possible mechanism of action. The gene discussed is CCND1; the disease is B-cell chronic lymphocytic leukemia.